353 324

Cited 10 times in

Overexpression of SOX2 Is Associated with Better Overall Survival in Squamous Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy

 Hong In Yoon  ;  Kyu Hyun Park  ;  Eun-Jung Lee  ;  Ki Chang Keum  ;  Chang Geol Lee  ;  Chul Hoon Kim  ;  Yong Bae Kim 
 CANCER RESEARCH AND TREATMENT, Vol.48(2) : 473-482, 2016 
Journal Title
Issue Date
Carcinoma, Squamous Cell/genetics* ; Carcinoma, Squamous Cell/physiopathology ; Carcinoma, Squamous Cell/therapy ; Disease-Free Survival ; Humans ; In Situ Hybridization, Fluorescence ; Lung Neoplasms/genetics* ; Lung Neoplasms/physiopathology ; Lung Neoplasms/therapy ; Radiotherapy, Adjuvant ; SOXB1 Transcription Factors/biosynthesis*
Carcinoma ; Lung neoplasms ; Overexpression ; Radiotherapy ; SOX-2 ; Squamous cell
PURPOSE: The purpose of this study is to investigate the prognostic significance of SOX2 gene amplification and expression in patients with American Joint Committee on Cancer stage III lung squamous cell carcinoma (SCC) who underwent surgery followed by adjuvant radiotherapy. MATERIALS AND METHODS: Pathological specimens were obtained from 33 patients with stage III lung SCC treated with surgery followed by adjuvant radiotherapy between 1996 and 2008. SOX2 gene amplification and protein expression were analyzed using fluorescent in situ hybridization and immunohistochemistry, respectively. Patients were divided into two groups according to their SOX2 gene amplification and protein expression status. Kaplan-Meier estimates and a Cox proportional hazards model were used to identify the prognostic factors affecting patient survival. RESULTS: The median follow-up period for surviving patients was 58 months (range, 5 to 102 months). SOX2 gene amplification was observed in 22 patients and protein overexpression in 26 patients. SOX2 overexpression showed significant association with SOX2 gene amplification (p=0.002). In multivariate analysis, SOX2 overexpression was a significant prognostic factor for overall survival (OS) (hazard ratios [HR], 0.1; 95% confidence interval [CI], 0.002 to 0.5; p=0.005) and disease-free survival (DFS) (HR, 0.15; 95% CI, 0.04 to 0.65; p=0.01). Age (HR, 0.33; 95% CI, 0.11 to 0.98; p=0.046) and total radiation dose (HR, 0.13; 95% CI, 0.02 to 0.7; p=0.02) were the independent prognostic factors for OS and DFS. Patients with SOX2 amplification did not show a longer OS (p=0.95) and DFS (p=0.48). CONCLUSION: Our data suggested that SOX2 overexpression could be used as a positive prognostic factor in patients with stage III lung SCC receiving adjuvant radiotherapy.
Files in This Item:
T201601263.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Keum, Ki Chang(금기창) ORCID logo https://orcid.org/0000-0003-4123-7998
Kim, Yong Bae(김용배) ORCID logo https://orcid.org/0000-0001-7573-6862
Kim, Chul Hoon(김철훈) ORCID logo https://orcid.org/0000-0002-7360-429X
Park, Kyu Hyun(박규현)
Yoon, Hong In(윤홍인) ORCID logo https://orcid.org/0000-0002-2106-6856
Lee, Eun Jung(이은정)
Lee, Chang Geol(이창걸) ORCID logo https://orcid.org/0000-0002-8702-881X
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.